Titlebook: Ways of Regulating Drugs in the 19th and 20th Centuries; Jean-Paul Gaudillière (Director),Volker Hess (Chai Book 2013 Palgrave Macmillan,

ALLEY

instate

,What’s in a Pill? On the Informational Enrichment of Anti-Cancer Drugs, in orange, the words ., ., and . pointed to a tiny pile of orange pills identified in a smaller headline: “Revolutionary new pills like GLEEVEC combat cancer by targeting only the diseased cells. Is this the breakthrough we’ve been waiting for?” Two years later, Daniel Vasella, Chairman and CEO of

placebo

Making Risks Visible: The Science, Politics, and Regulation of Adverse Drug Reactions,s linked to heart attacks. The scenarios involved in the recent cases of Baycol and Vioxx should be familiar. A novel drug passes intense regulatory scrutiny. The drug’s makers heavily promote it. Following widespread use, a previously unnoticed side effect is observed. Investigative journalists the

思想靈活

PET-scan

終點(diǎn)

Thalidomide, Drug Safety Regulation, and the British Pharmaceutical Industry: The Case of Imperial anagers, who have sometimes blamed the current dearth of new drugs on the increasingly complex and costly procedures involved in complying with the regulations imposed on them. As well as patenting, these have included pricing, and — most importantly — drug safety regulations. Indeed, as Gaudillière

打包

AZT and Drug Regulatory Reform in the Late 20th-Century US, story without reference to the rise of the AIDS epidemic and the efforts of AIDS activists. Their persistent calls for access to experimental drugs and changes in clinical protocol design for drug evaluation were highly influential in regulatory reforms implemented in the late 1980s and 1990s. On t

Chameleon

思考

控制